Aceclofenac

證據等級: L5

預測適應症: 10 個

Aceclofenac: From Anti-Inflammatory Pain Relief to Inflammatory Spondylopathy

One-Sentence Summary

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class, widely used internationally for osteoarthritis, rheumatoid arthritis, and pain management. The TxGNN model predicts it may be effective for Inflammatory Spondylopathy, with 3 clinical trials and 17 publications currently supporting this direction — notably including head-to-head RCTs demonstrating efficacy in ankylosing spondylitis, the prototypical inflammatory spondylopathy.

Quick Overview

Item	Content
Original Indication	Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain management (per international authorizations)
Predicted New Indication	Inflammatory Spondylopathy
TxGNN Prediction Score	99.63%
Evidence Level	L1 — ≥2 completed RCTs with head-to-head comparisons
NL Market Status	Not marketed
Number of Authorizations	0 (Netherlands)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Aceclofenac is a phenylacetic acid derivative that acts primarily through preferential inhibition of cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandin E2 (PGE2) and suppressing pro-inflammatory cytokines including IL-1β and TNF-α. This COX-2 selectivity profile offers a theoretical advantage over non-selective NSAIDs in terms of gastrointestinal tolerability, while maintaining potent anti-inflammatory and analgesic effects.

Inflammatory spondylopathy — a group of chronic inflammatory conditions affecting the axial skeleton, including ankylosing spondylitis (AS) — is fundamentally driven by the same prostaglandin and cytokine pathways that aceclofenac targets. NSAIDs are established as first-line therapy for inflammatory spondylopathies according to ASAS/EULAR guidelines, and continuous NSAID use has been shown to potentially slow radiographic progression in AS. The mechanistic overlap between aceclofenac’s pharmacology and the disease pathophysiology is therefore strong.

Importantly, aceclofenac is already authorized for ankylosing spondylitis in multiple countries (Spain, Portugal, and others in the EU), and head-to-head RCTs from the 1990s demonstrated efficacy comparable to indomethacin and tenoxicam in AS patients. This makes the TxGNN prediction not merely theoretical but well-supported by existing clinical evidence, suggesting that the gap is primarily regulatory (lack of NL marketing authorization) rather than scientific.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00647517	Phase 4	Completed	60	Taiwanese RCT evaluating tramadol/APAP as add-on to NSAID (including aceclofenac) in AS/RA patients. Directly relevant to aceclofenac use in inflammatory spondylopathy as baseline therapy.
NCT05164198	Phase 4	Unknown	448	Multicenter trial optimizing TNF inhibitor dose adjustment in AS patients with stable disease. Provides context on disease management and potential combination strategies with NSAIDs.
NCT02883569	N/A	Completed	1,102	Large comparative effectiveness study of surgery vs. non-surgery for low back pain. Indirectly relevant — provides natural history data for spinal inflammatory conditions.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8823692	1996	RCT	J Rheumatol	3-month multicenter double-blind RCT: aceclofenac 100 mg bid was as safe and effective as tenoxicam 20 mg in active AS patients.
8823693	1996	RCT	J Rheumatol	Multicenter controlled trial: aceclofenac demonstrated efficacy and tolerability comparable to indomethacin in active AS.
34876850	2021	Systematic Review	J Pain Res	Comprehensive review confirming aceclofenac’s analgesic and anti-inflammatory effects in musculoskeletal disorders including AS, OA, and RA.
15163279	2004	Review	Expert Opin Pharmacother	Aceclofenac effective in >75 million patients worldwide; proved comparable to tenoxicam, naproxen, and indomethacin in AS.
11511027	2001	Review	Drugs	Reappraisal confirming aceclofenac reduces joint inflammation, pain intensity, and morning stiffness in AS with favourable GI profile.
8799688	1996	Pharmacological Review	Drugs	Established aceclofenac’s efficacy equivalent to diclofenac/indomethacin in AS with lower GI damage potential.
20829199	2011	Guideline	Ann Rheum Dis	ASAS recommendations for NSAID intake reporting in axial spondyloarthritis — includes aceclofenac in NSAID equivalent scoring.
11523298	2001	Review	Rev Med Liege	Critical review of aceclofenac’s role in inflammatory pain; highlights anti-inflammatory profile including PGE2 inhibition and cartilage remodeling effects.
11548913	2001	Pharmacoeconomic	PharmacoEconomics	Economic analysis showing aceclofenac’s cost-effectiveness vs. other NSAIDs in arthritic disorders including AS, factoring in lower adverse event rates.
22350497	2012	Review (Safety)	Clin Drug Investig	Reviews gastroprotection strategies for NSAIDs in rheumatic disorders including AS; relevant to long-term aceclofenac safety planning.

Netherlands Market Information

Aceclofenac currently holds no marketing authorization (handelsvergunning) from the CBG-MEB in the Netherlands. The drug is not registered and not marketed in the Dutch market.

Item	Status
CBG-MEB Authorization	None
Market Availability	Not available
EMA Central Authorization	Not applicable (nationally authorized in other EU member states)

Note: Aceclofenac is authorized and marketed in several other EU member states (e.g., Spain, Portugal, Italy, Belgium) under various brand names (Biofenac, Airtal, Falcol). A mutual recognition or decentralized procedure could potentially facilitate Dutch authorization.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) from an authorizing EU member state for comprehensive safety information. Key considerations based on the NSAID drug class:

Class-wide NSAID warnings apply: cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, renal toxicity, and hepatotoxicity
Gastroprotection: Literature indicates aceclofenac has a more favourable GI profile compared to other NSAIDs (e.g., diclofenac, indomethacin), but co-prescription of a proton pump inhibitor should be considered for at-risk patients
Adverse drug reaction of note: One case report (PMID 16922973) documented generalized pustular psoriasis precipitated by aceclofenac

⚠️ Data Gap: Specific SmPC warnings, contraindications, and drug-drug interaction data for aceclofenac were not available in this evidence pack. These must be obtained from the SmPC of an EU-authorized product before clinical use can be considered.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Aceclofenac has robust Level 1 evidence supporting its efficacy in inflammatory spondylopathy (specifically ankylosing spondylitis), including two completed head-to-head RCTs, a systematic review, and multiple pharmacological reviews. The drug is already authorized for this indication in other EU member states, making the repurposing pathway primarily a regulatory rather than a scientific challenge. However, the absence of CBG-MEB authorization and the identified safety data gaps require attention before any clinical application in the Netherlands.

To proceed, the following is needed:

Obtain the SmPC from an EU-authorizing member state (e.g., Spain — AEMPS) for complete safety, contraindication, and interaction data
Evaluate feasibility of a mutual recognition procedure or Article 126a authorization for Dutch market access
Obtain detailed mechanism of action data from DrugBank to complete the pharmacological profile
Assess formulary positioning relative to currently available NSAIDs in the Netherlands (e.g., diclofenac, naproxen, etoricoxib) — determine whether aceclofenac offers a clinically meaningful advantage
Consider named-patient supply (artsenverklaring) pathway for individual patient access pending formal authorization

This report was generated on 2026-04-03 based on TxGNN model predictions and publicly available evidence. Results are for research purposes only and do not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.